Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if INAB is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
3 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 10
21 filers reported a long position in INAB for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Alyeska Investment Group, L.P. | $1.3M | 944.3K | Unchanged |
| FRANKLIN RESOURCES INC | $1.3M | 914.5K | Unchanged |
| 683 Capital Management, LLC | $1M | 724.6K | Unchanged |
| Stonepine Capital Management, LLC | $980.4K | 695.3K | +4.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | $126.5K | 88.9K | Unchanged |
| BIOS Capital Management, LP | $114.1K | 81K | -51.8% |
| GEODE CAPITAL MANAGEMENT, LLC | $102.3K | 72.6K | -15.9% |
| CITADEL ADVISORS LLC | $88.9K | 63.1K | New |
| OPPENHEIMER & CO INC | $88.9K | 63K | +162.3% |
| VANGUARD FIDUCIARY TRUST CO | $62K | 43.6K | Unchanged |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.